Comparative Pharmacology
Head-to-head clinical analysis: AMIDATE versus ETHRANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIDATE versus ETHRANE.
AMIDATE vs ETHRANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AMIDATE (etomidate) is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the GABA-A receptor at the beta-2/3 subunit, enhancing the inhibitory effects of GABA and producing rapid sedation and anesthesia.
Enflurane is a volatile inhalational anesthetic that potentiates GABA-A receptor activity and inhibits excitatory neurotransmission, resulting in general anesthesia.
0.2-0.6 mg/kg IV bolus for induction of anesthesia.
1-5% inspired concentration via inhalation, titrated to effect for maintenance of general anesthesia.
None Documented
None Documented
Terminal elimination half-life: 2.5–4 hours (adults); 1–2 hours (children); Prolonged in hepatic impairment or with continuous infusion.
Context-sensitive half-life: approximately 2-5 minutes after short procedures; prolonged after prolonged administration due to slow washout from fat stores.
Renal: <5% unchanged; Hepatic metabolism to carboxylic acid metabolite (inactive); Metabolite renally eliminated; Fecal: negligible.
Primarily exhaled unchanged via lungs (>95%); less than 5% metabolized in liver to fluoride ion and other metabolites, with renal excretion of metabolites.
Category C
Category C
General Anesthetic
General Anesthetic